83 related articles for article (PubMed ID: 23357978)
1. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
2. The Expression and Activation of the NF-κB Pathway Correlate with Methotrexate Resistance and Cell Proliferation in Acute Lymphoblastic Leukemia.
Canevarolo RR; Cury NM; Yunes JA
Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895229
[TBL] [Abstract][Full Text] [Related]
3. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
[TBL] [Abstract][Full Text] [Related]
4. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
5. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF-κB inhibition and the induction of oxidative stress.
Costa RGA; Oliveira MS; Rodrigues ACBDC; Silva SLR; Dias IRSB; Soares MBP; de Faro Valverde L; Gurgel Rocha CA; Dias RB; Bezerra DP
J Cell Mol Med; 2024 Apr; 28(8):e18333. PubMed ID: 38652192
[TBL] [Abstract][Full Text] [Related]
7. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
10. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.
Pakjoo M; Ahmadi SE; Zahedi M; Jaafari N; Khademi R; Amini A; Safa M
Cell Commun Signal; 2024 Feb; 22(1):105. PubMed ID: 38331801
[TBL] [Abstract][Full Text] [Related]
11. Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.
Liu J; Zhang L; Guo L; Zeng Y; Guo Q; Yang C; Shu J; Liu W; Yang L
Bioorg Med Chem; 2022 Dec; 75():117085. PubMed ID: 36395680
[TBL] [Abstract][Full Text] [Related]
12. Repurposing anthelmintic agents to eradicate resistant leukemia.
Mezzatesta C; Abduli L; Guinot A; Eckert C; Schewe D; Zaliova M; Vinti L; Marovca B; Tsai YC; Jenni S; Aguade-Gorgorio J; von Stackelberg A; Schrappe M; Locatelli F; Stanulla M; Cario G; Bourquin JP; Bornhauser BC
Blood Cancer J; 2020 Jun; 10(6):72. PubMed ID: 32591499
[TBL] [Abstract][Full Text] [Related]
13. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.
Accordi B; Espina V; Giordan M; VanMeter A; Milani G; Galla L; Ruzzene M; Sciro M; Trentin L; De Maria R; te Kronnie G; Petricoin E; Liotta L; Basso G
PLoS One; 2010 Oct; 5(10):e13552. PubMed ID: 21042412
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.
Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM
Cell Rep; 2019 Nov; 29(6):1675-1689.e9. PubMed ID: 31693904
[TBL] [Abstract][Full Text] [Related]
15. [Expression and Significance of Vitamin D Receptor Gene and NF-κB Pathway in Blood of Children with Acute Lymphoblastic Leukemia].
Yilisuya P; Hailiqiguli N; Yan M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1624-1628. PubMed ID: 38071037
[TBL] [Abstract][Full Text] [Related]
16. Targeting nucleolin improves sensitivity to chemotherapy in acute lymphoblastic leukemia.
Chen Y; Wu Z; Wang L; Lin M; Jiang P; Wen J; Li J; Hong Y; Zheng X; Yang X; Zheng J; Gale RP; Yang T; Hu J
Cell Oncol (Dordr); 2023 Dec; 46(6):1709-1724. PubMed ID: 37486460
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia.
Turati VA; Guerra-Assunção JA; Potter NE; Gupta R; Ecker S; Daneviciute A; Tarabichi M; Webster AP; Ding C; May G; James C; Brown J; Conde L; Russell LJ; Ancliff P; Inglott S; Cazzaniga G; Biondi A; Hall GW; Lynch M; Hubank M; Macaulay I; Beck S; Van Loo P; Jacobsen SE; Greaves M; Herrero J; Enver T
Nat Cancer; 2021 Aug; 2(8):835-852. PubMed ID: 34734190
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.
van Leeuwen FN
Haematologica; 2020 Jan; 105(1):10-11. PubMed ID: 31894096
[No Abstract] [Full Text] [Related]
19. Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy.
Cox WPJ; Evander N; Van Ingen Schenau DS; Stoll GR; Anderson N; De Groot L; Grünewald KJT; Hagelaar R; Butler M; Kuiper RP; Van der Meer LT; Van Leeuwen FN
Haematologica; 2023 Dec; 109(6):1755-65. PubMed ID: 38124624
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.
Murphy B; Yin H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Kurmasheva RT; Dvorchik I; Wu J; Billups CA; Boateng N; Smith MA; Lock RB; Houghton PJ
Cancer Res; 2016 Oct; 76(19):5798-5809. PubMed ID: 27496711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
